Kymera Therapeutics Inc annual free cash flow for fiscal TTM was -$237 million, a decrease of 1.3% from -$234 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($237M) | ($234M) | ($207M) | ($137M) | ($156M) | ($131M) | $79M | $17M | ($19M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($54M) | ($89M) | ($67M) | ($27M) | ($61M) | ($80M) | ($63M) | ($50M) | ($48M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More KYMR metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All KYMR financial statements → Interactive KYMR charts →
About TickerBase · Data methodology & sources · Privacy · Terms